MyLymphomaTeam

Brukinsa (zanubrutinib) has been shown to be effective for several types of non-Hodgkin lymphoma. It's specifically approved to treat mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and follicular lymphoma in Show Full Answer

Brukinsa (zanubrutinib) has been shown to be effective for several types of non-Hodgkin lymphoma. It's specifically approved to treat mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and follicular lymphoma in certain circumstances. The medication is typically taken as a pill once or twice daily. Common side effects may include anemia, neutropenia, rash, bruising, diarrhea, and cough. It's important to note that more serious side effects can occur, including hemorrhage, infections, and liver problems. Regular monitoring by your healthcare team is essential while taking this medication.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Oral Treatments vs. Chemotherapy for Indolent Non-Hodgkin Lymphoma (NHL)